SARS-CoV-2 continues to evolve, with Omicron-descendant and other variants driving recurring surges across the United States and globally. In response, both the WHO and King County recommend annual vaccination for all individuals, but especially for high-risk groups. These vaccines seek to elicit one of the body’s primary defenses against viral infection: neutralizing antibodies. Antibodies block viral infection of the host cell by binding to an epitope, a specific region of a viral protein. To-date, most of the potent neutralizing antibodies bind the receptor-binding domain (RBD) of the Spike protein. However, virus-host interactions are incredibly dynamic. SARS-CoV-2 can undergo mutations in Spike to reduce antibody binding without disrupting Spike function, ultimately allowing the virus to escape antibody-mediated protection. With new variants emerging each season, there is a critical need for antibodies that protect against diverse strains of SARS-CoV-2 and related-viruses. But how do antibodies that neutralize across viral variants emerge?
Prior research hints that exposure to multiple Spike antigens induces a broad plasma neutralizing antibody response, but the individual antibodies that coordinate this response are unknown. The Overbaugh lab at the Fred Hutch Cancer Center leveraged peripheral blood mononuclear cell (PBMC) samples from the Hospitalized or Ambulatory Adults with Respiratory Viral Infections (HAARVI) cohort, through a collaboration with Dr. Helen Chu at the University of Washington, to tackle this question. In a recent mBio publication, former research technician Michelle Lilly and colleagues investigated how re-infection shapes the Spike-specific antibody profile of the study participant C68. This individual was immunized with two doses of the Pfizer-BioNTech mRNA vaccine and importantly, had a history of multiple SARS-CoV-2 infections.
One year after their initial Delta infection, the individual C68 experienced another breakthrough infection when Omicron was the predominant circulating strain. Spike-specific B cells were isolated following the second infection and the heavy and light chain genes, which encode major antibody characteristics, were amplified by PCR and sequenced. The randomly assorted gene segments called variable, diversity, and joining (VDJ) of the heavy chain were used as unique identifiers to track clonal antibody lineages. Lilly and colleagues discovered four antibody lineages clonally related to those elicited by the first infection, and nine distinct RBD-specific lineages, emerging after the two breakthrough infections.
With the hope of identifying cross-neutralizing antibodies, the authors characterized and compared the profiles of Spike-specific antibodies between the individual C68’s two breakthrough infections. In the second breakthrough infection, all clonally related antibodies exhibited evidence of somatic hypermutation, the iterative process through which heavy chain genes acquire random mutations during maturation to produce higher-affinity binding antibodies. Notably, these antibodies displayed breadth in binding across multiple SARS-CoV-2 variants (Wuhan, Delta, Omicron), and nearly all showed similar or improved neutralization compared to its earlier counterpart from the first infection, supporting the hypothesis that repeated antigen exposure can improve both antibody binding and neutralization breadth.
Not all antibodies are created equal, however. When Lilly characterized the clonally distinct antibody lineage, the authors observed strong binding breadth against multiple SARS-CoV-2 variants and diverse sarbecovirus clades, including SARS-CoV-1. One remarkable antibody, C68.490, neutralized SARS-CoV-1 ten-fold better than all other tested antibodies. Authors engineered yeast cell lines expressing RBD proteins representing 72 sarbecoviruses and showed that C68.490 bound all RBD proteins, with breadth surpassing that of all other known broadly reactive sarbecovirus antibodies (VIR-7229, SA55, SX259). C68.490 also neutralized all seven sarbecovirus strains tested, despite no evidence of prior exposure. A deep mutational scanning (DMS) library encoding all single mutations in the RBD protein revealed that C68.490 bound a highly conserved epitope at amino acid residues 378 and 384. Unlike most monoclonal antibodies, which target the ACE2-binding site of RBD, and thus are easily susceptible to escape mutations, C68.490’s conserved epitope allows for its exceptional breadth.
Investigating the biological determinants of what makes an antibody better not only improves our understanding of human immunology but can also be leveraged for future vaccine design. The authors show that clonal lineages emerging following chronic antigen exposure from multiple infections, display greater binding breadth and neutralization. Lilly remarks that “While monoclonal antibodies therapies were utilized early in the Covid-19 pandemic, these treatments were rendered ineffective by the emergence of new viral variants. An antibody like C68.490, with broad activity across both SARS-CoV-2 variants and other sarbecoviruses, could be used to develop new SARS-CoV-2 therapeutics, as well as be a useful tool against potential future sarbecovirus spillover events.” As SARS-CoV-2 and seasonal coronaviruses persist, identifying broadly neutralizing antibodies with cross-clade activity remains a critical tool in the ongoing host-pathogen arms race.
The spotlighted research was funded by the National Institutes of Health, Searle Scholars Program, National Science Foundation Graduate Research Fellowship Program, Washington Research Foundation, and Boehringer Ingelheim.
Lilly M, Ruiz F, Foreman WB, Chohan V, Guenthoer J, Depierreux D, Baharani VA, Ralph D, Harteloo A, Chu HY, Bieniasz PD, Starr TN, Overbaugh J. 2026. Re-infection with SARS-CoV-2 is associated with increased antibody breadth and potency against diverse sarbecovirus strains. mBio. DOI: 10.1128/mbio.03612-25.